The comparison of alfa glucosidase inhibitor or glinide based DPP-4 inhibitor combination therapy in drug-naive type 2 diabetic patients.

The comparison of alfa glucosidase inhibitor or glinide based DPP-4 inhibitor combination therapy in drug-naive type 2 diabetic patients. - The comparison of alfa GI or glinide based DPP-4 inhibitor combination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016011

Enrollment

Registered

2014-12-19

Start date

2012-03-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

miglitol 150mg and alogliptin 25mg repaglinide 0.75mg and alogliptin 25mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient treated with only a dietetic therapy more than three months with the value of HbA1c more than 7.0% less than 9.0%.

Exclusion criteria

Exclusion criteria: An antidiabetic is given. The patient have serious liver dysfunction. The patient have moderate or severe renal dysfunction. The patient have a malignant tumor. The patient become pregnant or may become pregnant.

Design outcomes

Primary

Measure	Time frame
Glycemic control improvement effect and hypoglycaemic attack frequency	—

Secondary

Measure	Time frame
postprandial serum glucose and lipids improvement effect, change of the serum insulin and incretin level	—

Countries

Japan

Contacts

Public ContactFumitaka Okajima

Nippon Medical School Choba Hokusoh Hospital Division of Endocrinology

okaji@nms.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026